FIGURE 2. Comparison of metabolism of ¹¹¹In-2IT-BAD-Lym-1 in NHL patients (A), ¹¹¹In-2IT-BAD-m170 in prostate cancer patients (B), and ¹¹¹In-2IT-BAD-m170 in breast cancer patients (C). Of ¹¹¹In-2IT-BAD-Lym-1 or ¹¹¹In-2IT-BAD-m170 in patients’ plasma at specific points in time, percentage in monomeric (•), metabolite (), and complexed () forms was measured by HPLC. In NHL patients receiving ¹¹¹In-2IT-BAD-Lym-1, metabolites and complexes constituted substantially larger fractions of ¹¹¹In in plasma compared with prostate and breast cancer patients receiving ¹¹¹In-2IT-BAD-m170. Decay-corrected mean percentage injected dose (%ID) of ¹¹¹In in patients’ blood decreased over time (dashed lines). Thus, metabolites and complexes of ¹¹¹In-2IT-BAD-Lym-1 showed relative growth over time as fractions of total ¹¹¹In activity, but not absolute growth in terms of %ID.